BIO.News Newsletter

BIO’s Phyllis Arthur will testify at the House Energy and Commerce Health Subcommittee about pandemic preparedness—we’ll recap tomorrow. In the meantime, Merck and the U.S. Chamber of Commerce filed lawsuits calling the drug price controls unconstitutional, and BIO and CSBA released a report highlighting best practices to grow their bioscience sectors. (736 words, 3 minutes, 40 seconds)

FDA advisors voted unanimously on Friday to recommend traditional approval for Leqembi—here’s what happened and the next steps. Plus, while you were convention-ing, there was talk around the world about IP waivers. (671 words, 3 minutes, 20 seconds)

What a week! We catch up on all the news about Mexico, Merck, and Leqembi—plus, give you a few inspiring takeaways from the BIO International Convention. Enjoy the weekend. (623 words, 3 minutes, 6 seconds)

Wednesday at the BIO International Convention was all about policy—from the FDA Commissioner talking about Accelerated Approval and challenges to the FDA’s authority, to panels on price controls and state advocacy. A few highlights below, plus what you might have missed in D.C. this week. (581 words, 2 minutes, 54 seconds)

Busiest Tuesday ever? What Massachusetts Gov. Maura Healey, Katie Couric, and Dr. Ted W. Love said at the BIO International Convention yesterday, plus news from D.C. on IP, R&D amortization, and BIO’s new state economic development report—and we still kept it under 1,000 words. (887 words, 4 minutes, 26 seconds)

Collaboration is key—whether we’re growing biotech jobs and startups, or addressing infectious diseases with pandemic potential. Are we ready? Here’s what we learned on Day 1 of the BIO International Convention, and what’s ahead today. Plus, BIO elects a new board chair and executive committee members.  (768 words, 3 minutes, 50 seconds)

The 2023 BIO International Convention kicks off today, and the Good Day BIO and Bio.News team is on the ground in Boston to bring you the news and highlights. Below, what we’re watching plus news about the biotech workforce, pandemic preparedness, and future partnerships. (584 words, 2 minutes, 55 seconds)

Medicare doubles down on its decision to only cover a new class of Alzheimer’s drugs with participation in a registry—an announcement that continues to create a barrier for patients and undermines the FDA’s accelerated approval process. (551 words, 2 minutes, 45 seconds)

A new study highlights the devastating impact of the Inflation Reduction Act’s drug price controls—plus, the FDA approved the second-ever RSV vaccine, bringing the total to two in one month. (480 words, 2 minutes, 24 seconds)

The House passed two bills—that BIO supports—that would help biotech startups. Plus, a recent poll finds likely voters want Medicare to cover FDA-approved Alzheimer’s treatments. (606 words, 3 minutes, 1 second)